Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics

• Published in: American journal of translational research 2021-01, Vol.13 (4), p.3868-3889
• Main Authors: Allemailem, Khaled S, Almatroudi, Ahmad, Alrumaihi, Faris, Makki Almansour, Nahlah, Aldakheel, Fahad M, Rather, Rafiq Ahmad, Afroze, Dil, Rah, Bilal
• Format: Article
• Language: English
• Subjects: Review
• ISSN: 1943-8141; 1943-8141

Prostate cancer is one of the most frequently diagnosed malignancies in developed countries and approximately 248,530 new cases of prostate cancer are likely to be diagnosed in the United States in 2021. During the late 1990s and 2000s, the prostate cancer-related death rate has decreased by 4% per year on average because of advancements in prostate-specific antigen (PSA) testing. However, the non-specificity of PSA to distinguish between benign and malignant forms of cancer is a major concern in the management of prostate cancer. Despite other risk factors in the pathogenesis of prostate cancer, recent advancement in molecular genetics suggests that genetic heredity plays a crucial role in prostate carcinogenesis. Approximately, 60% of heritability and more than 100 well-recognized single-nucleotide-polymorphisms (SNPs) have been found to be associated with prostate cancer and constitute a major risk factor in the development of prostate cancer. Recent findings revealed that a low to moderate effect on the progression of prostate cancer of individual SNPs was observed compared to a strong progressive effect when SNPs were in combination. Here, in this review, we made an attempt to critically analyze the role of SNPs and associated genes in the development of prostate cancer and their implications in diagnostics and therapeutics. A better understanding of the role of SNPs in prostate cancer susceptibility may improve risk prediction, enhance fine-mapping, and furnish new insights into the underlying pathophysiology of prostate cancer.